Dropout is a common problem in longitudinal cohort studies and clinical trials, often raising concerns of nonignorable dropout. Selection, frailty, and mixture models have been proposed to account for potentially nonignorable missingness by relating the longitudinal outcome to time of dropout. In addition, many longitudinal studies encounter multiple types of missing data or reasons for dropout, such as loss to follow-up, disease progression, treatment modifications and death. When clinically distinct dropout reasons are present, it may be preferable to control for both dropout reason and time to gain additional clinical insights. This may be especially interesting when the dropout reason and dropout times differ by the primary exposure variable. We extend a semi-parametric varying-coefficient method for nonignorable dropout to accommodate dropout reason. We apply our method to untreated HIV-infected subjects recruited to the Acute Infection and Early Disease Research Program HIV cohort and compare longitudinal CD4 þ T cell count in injection drug users to nonusers with two dropout reasons: anti-retroviral treatment initiation and loss to follow-up.
Introduction
Longitudinal studies are ubiquitous in the medical and epidemioligcal literature. However, dropout is common, raising concerns of bias due to nonignorable missing data. In the presence of nonignorable dropout, estimates from traditional analyses are biased towards subjects with longer follow-up, which can obscure important relationships. 1, 2 There has been much research on selection, 3, 4 frailty, 5, 6 and mixture models 7, 8 to account for potentially nonignorable missingness by relating the longitudinal outcome to time of dropout.
In addition, many longitudinal studies encounter multiple types of missing data or reasons for dropout, such as loss to follow-up, disease progression, treatment modifications, and death. When clinically distinct dropout reasons are present, it is not clear that adjustment for reason is needed to improve bias or efficiency in the marginal estimate of the outcome or change in the outcome over time. However, investigators are often uncomfortable averaging results over dropout reason, particularly when dropout reasons and times differ by the primary exposure variable. Pauler et al. 9 considered classifying missing data patterns by dropout reason in a pattern mixture model (PMM) and reported dropout reason specific estimates. In this example, dropout reasons included loss to follow-up, such that the patient was still alive but did not return for study visits, and death, where the additional visits did not exist in theory. Accounting for dropout reason may also allow for additional clinically important insights that increase understanding of the dropout mechanism and what drives differences between exposure groups. For example, within dropout reasons, there may be no differences between the exposure groups, but given the differing dropout reason distributions, an exposure effect may be realized in the marginal estimate. Therefore, it is clinically useful to adapt existing dropout approaches to account for dropout reason. In addition, considering dropout reason in the analysis may improve model fit, particularly if the forms of the dropout varying slopes are quite different across dropout reasons or are very complex. In this paper, we extend a semi-parametric varying-coefficient model 10, 11 that allows regression coefficients to vary smoothly according to unknown functions of dropout time to also account for dropout reason. Our approach allows for estimation of both dropout reason specific and marginal effects of time and differences in the effect of time by exposures or treatments.
Example
Longitudinal HIV cohorts provide an opportunity for studying the impact of illicit drug use on disease progression. After initiating antiretroviral therapy, it is well established that hard drug users have poorer outcomes, in part due to less faithful adherence to treatment regimens. 12 Illicit drug use has also been hypothesized to accelerate disease progression by directly enhancing virus replication and impairing immune responses; however, among untreated subjects, there are inconsistent findings for the effect of drug use. While in vitro and animal studies suggest that drugs and alcohol impair immune function and increase HIV replication, [13] [14] [15] epidemiological studies of drug use and longitudinal CD4 þ count and HIV-1 RNA in untreated subjects have been mixed, with some studies showing no association, [16] [17] [18] [19] [20] others finding accelerated disease progression among drug users, [21] [22] [23] and some even finding slower progression. 24, 25 These conflicting results may be linked to differential dropout mechanisms between drug users and nonusers. In illicit drug users, multiple factors could lead to adverse outcomes, including consequences of substance abuse and liver disease, as well as sub-optimal engagement in HIV care, which could contribute to differential dropout. 26 Thus, study completers may have improved outcomes and be less likely to engage in drug use compared to those who drop out. 27 In this paper, we consider the effect of injection drug use on disease progression in untreated, HIV-infected subjects enrolled in the multicenter Acute Infection and Early Disease Research Program (AIEDRP) cohort. Given subjects are recruited with early HIV infection, dropout is primarily due to anti-retroviral treatment initiation or loss to follow-up. In the AIEDRP cohort we have the potential for both the dropout reason and the dropout time distribution to vary by the exposure variable, injection drug use, providing motivation to accommodate both dropout reason and dropout time in the analysis.
Statistical methods
The use of mixtures of random effects models to adjust for potentially nonignorable dropout in longitudinal studies has been described by several authors. 8, [28] [29] [30] Mixture models account for dropout by factoring the joint distribution of the outcome, y, and dropout time, u, as the product of the conditional distribution of the outcome for a given dropout time and the distribution of dropout times, f ð y, uÞ ¼ f ð yjuÞ f ðuÞ, and the full-data response distribution f(y) is given by R f ð yjuÞdFðuÞ. Varying coefficient models (VCM) 31 provide a general framework for fitting the conditional distribution f ð yjuÞ by modeling regression coefficients as functions of dropout time. Wu and Bailey's conditional linear model (CLM), which assumes regression coefficients are polynomial functions of dropout time, as well as PMM's, which assume regression coefficients depend on a discrete set of dropout patterns, can be viewed as special cases of VCMs. 1 Semiparametric VCM's utilizing penalized splines and natural cubic B-splines have also been proposed. 11, 32 Unlike PMMs, these models allow for dropout at any continuous point in time and are also more flexible than the CLM, only requiring that regression coefficients are smooth, continuous functions of dropout time. Since outcomes for a subject are not observed after his or her dropout time, u, mixture models require assumptions about the behavior of the unobserved outcomes that occur after u. It is usual to assume that the relationship between the outcome and time is the same prior to and after u, and sensitivity analyses are required to determine if results are robust to reasonable violations of this assumption.
Extending varying-coefficient models to account for dropout reason
We extend semi-parametric VCMs that account for dropout time to adjust for dropout reason as well. Let h ¼ {1,. . .,H} denote dropout reason, g ¼ {1,..,G} represent group, such exposure or treatment groups that are to be compared, m g be the number of subjects in group g, and m hj g be the number of subjects with dropout reason h in group g, where the ith subject has n i observations and dropout time u i . The joint distribution of y, u, and h, is f ð y, u, hj gÞ ¼ f ð yj g, h, uÞ f ðuj g, hÞ pðhj gÞ, where the first term is the outcome model given dropout time and reason, the second is the model of dropout times given dropout reason, and the third the probability of dropout reason h. We follow a traditional longitudinal modeling framework, where y, given dropout time, reason, and group is assumed to be normally distributed, and within group, dropout reason is multinomial. The distribution of dropout times given reason and group is unspecified.
The subject-specific model of a continuous outcome is
where Y i , 1 i , t i and i are n i Â 1 vectors of outcomes, 1's, observation times and normally distributed errors, respectively. g i h i 0 ðu i Þ and g i h i 1 ðu i Þ are the dropout-varying coefficients for subjects in group g with dropout reason h. C i is an n i Â p matrix of covariates, which may also include covariate interactions with time, and b c are the associated coefficients. The random intercept, i0 , and slope, i1 , are distributed N(0, D), where
Þ. This model reduces to a standard linear mixed model, which does not depend on dropout time or reason, if h i g i 0 ðuÞ ¼ g i 0 and h i g i 1 ðuÞ ¼ g i 1 .
Calculation of dropout reason-specific and marginal effects
The expected value of the outcome at time t given dropout reason, group and the covariates is
E½YðtÞj g, h, C is also a linear function of time, so that the marginal coefficients for each dropout reason and group combination, gk (h), are given by
where k ¼ 0 for the intercept and k ¼ 1 for the slope. If Fðuj g, h, CÞ ¼ Fðuj g, hÞ, meaning that the distribution of dropout times depends only on group and dropout reason and not on additional covariates, then gk ðhÞ ¼ E½ ghk ðuÞj g, h, and the dropout reason specific slope can be estimated from the empirical distribution of dropout times in group g with dropout reason h. Define u 0
hjg ¼ ðu 0 1 hj g , . . . , u 0 R hj g Þ T as the vector of R hj g ordered dropout times for subjects with dropout reason h in group g, Å ujh, g as the vector of R hj g proportions of subjects with dropout reason h in group g with each dropout time u 0 r hj g (vector of proportions with denominator m hj g ), and Å hjg as the vector of H proportions of subjects with each dropout reason h in group g (vector of m hj g m g ). The marginal coefficients for each dropout reason are then estimated gk ðhÞ ¼
This is a weighted average of the dropout varying coefficients over the unique dropout times for dropout reason h in group g. It is equivalent to taking the average of the dropout varying coefficients for each subject with dropout reason h in group g gk ðhÞ ¼
Marginal coefficients averaged over dropout reason for each group, Ã gk , can be obtained as well
where gk ðhÞ is the H Â 1 vector of estimated dropout reason specific coefficients for group g. These coefficients can be interpreted as the population average of the outcome at baseline ( Ã g0 ) and the population average change in the outcome per unit time ( Ã g1 ) for group g given other covariates in the model. If the assumption that the distribution of dropout times does not depend on the covariates is inappropriate, it may not always be possible to easily estimate marginal coefficients, 1, 33 particularly in more complex cases where the distribution of dropout times may depend on continuous covariates or several different covariates. However in simple cases, where the distribution of dropout times depends on a few categorical covariates, using the empirical distribution of dropout times is a straightforward method that does not require distributional assumptions.
Differing forms of the dropout time and reason varying-coefficient model
Depending on assumptions, varying coefficient models can account for group, dropout time and reason in several different frameworks ( Figure 1 ). H ¼ 1 provides the traditional varying-coefficient model accounting for dropout time, but not reason (Figure 1(a) ). In equation (1), each dropout reason and group combination is allowed to have a distinct functional form for the dropout-varying coefficients (Figure 1(b) ). Special cases include permitting the dropout-varying coefficients to include a group effect that depends on dropout reason but not dropout time or assuming the effect of group does not depend on dropout reason (Figure 1 (c) and (d), respectively). These models may be advantageous when sample sizes are low in certain dropout reason and group combinations, which may make it unreasonable to estimate a distinct functional form of the dropout varying coefficients for all dropout reason and group combinations.
Fitting the varying-coefficient model with natural cubic B-splines
As in Forster et al., 11 this method utilizes natural cubic B-spline basis functions. Here, the lower boundary knot can be shifted inwards to increase the stability of coefficients for early dropout times where data may be sparse. Let u hj g be the set of dropout times observed in group g with dropout reason h. The conditional varying-coefficient model accounting for dropout time and reason is
whereũ ghijk ¼Bðu hj g , J ghk Þ ½i,jþ1 , for k ¼ 0, 1. For j > 0,Bðu hj g , J ghk Þ is the matrix of natural cubic B-spline basis functions with J ghk degrees of freedom andBðu hj g , J ghk Þ ½,1 ¼ 1. This matrix can be calculated in R using the ns() function in the splines package.Bðu hj g , J ghk Þ ½i,jþ1 indicates the element in the ith row and j þ 1th column of thẽ Bðu hj g , J ghk Þ matrix. The ith subjects dropout-varying-coefficients are given by
Estimation
These models can be fit in SAS Proc Mixed or R packages nlme and lme4 using restricted maximum likelihood estimation or maximum likelihood estimation. As the marginal estimates depend on an empirical dropout distribution, a bootstrap is used to obtain estimates of the standard errors and 95% confidence intervals (CI). R and SAS code to fit this model on a simulated dataset are available in the online Web Appendix (available at: http://smm.sagepub.com/).
Adjusting for dropout in the association of injection drug use and CDþ T cell decline
To demonstrate the impact of accounting for dropout time and reason on the analysis of CD4 þ count in untreated HIV, we analyze data from untreated subjects enrolled in the Acute Infection and Early Disease Research Program (AIEDRP). Investigating disease progression in untreated populations eliminates the well-described problem of Figure 1 . Examples of relationships between dropout time, reason, and group. Panel A depicts a varying-coefficient model with a group effect that does not account for dropout reason. In Panel B, dropout reason is accounted for and a different functional form of the slope is allowed for each dropout reason and group combination. In Panel C, the functional form of the slope depends only on dropout reason and not group. This is the model used to account for dropout time and reason in the application. In Panel D, the functional form of the slope depends only on dropout reason, and in addition, the effect of group is assumed to be the same across dropout reasons.
less faithful adherence to treatment regimens among injection drug users compared to others. 34 We hypothesized that after accounting for dropout time and reason, untreated HIV seropositive injection drug users experience steeper declines in CD4 þ count compared to untreated nonusers. AIEDRP was a multicenter, observational cohort study of subjects identified during early HIV infection. 35 Inclusion criteria have been described elsewhere. 35 Subjects were recruited between 1997 and 2007 at sites throughout the United States, Australia, Canada, and Brazil and, with physician guidance, self-selected when and whether to initiate anti-retroviral therapy. The study closed in 2008. Subjects were classified at enrollment with either acute or recent HIV infection if they presented within 2 weeks or 3 weeks to 12 months of seroconversion, respectively. 35 Since all subjects were enrolled during early infection, the AIEDRP dataset presents a unique opportunity to compare longitudinal outcomes between injection drug users and nonusers while avoiding differences in disease progression due to varying infection duration. CD4 þ counts generally decline during the high titer viremia of acute infection, and subsequently recover, at least partially, in concert with development of the immune response and declines in viremia. 36 Subsequently, CD4 þ counts decline over time in untreated individuals. Subjects in both the acute and recent HIV infection groups demonstrated these patterns of early CD4 þ count decline and recovery followed by long term declines. Fluctuations ceased for the majority of subjects by 5 weeks after enrollment (data not shown). Therefore, only observations obtained after week 5 were included in the analysis. Nadir CD4 þ count from this initial 5-week period was adjusted for in all analyses.
Data from 1059 AIEDRP subjects who did not immediately initiate antiretroviral therapy and who had at least one qualifying HIV-1 RNA measurement were evaluated. Baseline data were collected on race/ethnicity, age, sex, HIV risk factors, HIV-1 RNA, and CD4 þ count. Descriptive statistics are presented in Table 1 . Similar to other HIV seroconverter studies, 37 the AIEDRP cohort was biased towards white, homosexual men with a smaller proportion of women, non-whites, and injection drug users than the than the overall population of HIV-infected individuals in the AIEDRP countries. Many AIEDRP subjects were also recruited into clinical trials, such that subjects were also more likely to initiate therapy. Seventy-six (7.2%) subjects were classified as injection drug users according to self-reported HIV-risk behaviors at study entry. As subjects were recent seroconverters, this indicates recent exposure; however, since self-reported injection drug use was collected only at baseline, individuals who initiated or stopped injecting drugs after study entry, or misrepresented their drug history may be incorrectly categorized. In addition, we are unable to consider other illicit drug use categories as these data were not collected. HIV-1 RNA and CD4 þ count were measured at 2, 4, and 12 weeks, and then every 12 weeks until week 168, and every 24 weeks thereafter. Since few subjects had greater than 3 years of untreated follow-up, the analysis was limited to visits occurring within 3 years of enrollment, and subjects that had a full 3 years of follow-up were considered ''completers'' and assigned a dropout time of 1096 days. The most recent log 10 (HIV-1 RNA) between enrollment and the first CD4 þ count included in the model (viral load) and the nadir CD4 þ count from the initial 5-week period were considered as predictors in a model of log e (CD4 þ ). 38 
Methods
Subjects had incomplete untreated CD4 þ count data if they were lost to follow-up or initiated antiretrovial therapy. Overall, injection drug users tended to dropout earlier than nonusers and were less likely to be removed from the analysis due to treatment initiation ( Table 1 ). Among those who started treatment, injection drug users and other subjects had a similar range of dropout times; however, among those lost to follow-up, injection drug users dropped out earlier. Graphical analyses of subject-specific trajectories of log e (CD4 þ ) suggested that earlier dropouts had steeper declines in CD4 þ count than completers (Figure 2 ). Since the outcome is related to dropout time, dropout may be nonignorable. As there are two distinct reasons for dropout, dropout reason is also considered.
Log e (CD4 þ ) was modeled as a function of injection drug use and time with dropout reason and dropout timevarying B-spline bases for the slopes in the fixed effects and a random intercept and slope. A separate dropoutvarying slope was assumed for subjects lost to follow-up and those who started treatment. An interaction between injection drug use, dropout reason, and time was included to allow injection drug users to have different changes in CD4 þ count over time compared to nonusers who dropped out for the same reason. Additional covariates included age, race, sex, disease status (acute vs. recent HIV infection groups), log e (nadir CD4 þ ), log 10 (viral load) and time interactions with disease status, log e (nadir CD4 þ ), and log 10 (viral load). For B-splines, a maximum of 5 degrees of freedom was considered for each dropout-varying effect, with knots placed at the quantiles of the dropout distribution. Models with varying degrees of freedom were fit using maximum likelihood and a model was chosen based on Akaike information criterion (AIC). A final model was fit using restricted maximum likelihood estimation. For stable slope estimation, the lower boundary knot was set to week 24, corresponding to approximately four observations per subject. The final model had the following form This is similar to the model shown in Figure 1(c) . To test the hypotheses, 1000 bootstrap samples were drawn. Standard errors, estimated as the standard deviation of the bootstrap estimates, were used to perform Z-tests, and calculate 95% CIs. A traditional mixed model that did not account for dropout (log e ðCD4 þ Þ i ¼ 1 i g i 0 þ g i 1 t i þ C i b c þ 1 i i0 þ t i i1 þ i ) and a model that accounted only for dropout time but not reason ðlog e ðCD4 þ Þ i ¼ 1 i g i 0 þ g i 1 t i þ 2 ðu i Þt i þ C i b c þ 1 i i0 þ t i i1 þ i Þ were fit to compare results.
Results

Accounting for dropout time and reason
For log e (CD4 þ ), dropout-varying slopes for representative subjects are shown in Figure 3 with steeper declines (more negative slope) associated with earlier dropout. Controlling for age, sex, race, log e (nadir CD4 þ ), viral load, and acute infection, injection drug use was associated with more rapid declines in CD4 þ count ( Table 2 and Figure 4 ). For an injection drug user with recent infection, median nadir CD4 þ count of 500 and median viral load of 4:45 log 10 (copies/mL), CD4 þ counts declined by 31.2% per year (95% CI: 24.3%, 37.4%), compared to 24.4% per year (95% CI: 21.0%, 27.6%) for a nonuser.
Consistent with concurrent treatment guidelines, steeper CD4 þ count decline was also associated with treatment initiation. Subjects that were removed from the analysis at treatment initiation demonstrated a more rapid CD4 þ count decline of 38.3% per year (95% CI: 31.8%, 44.2%) than those who were lost to follow-up with Among subjects lost to follow-up, injection drug users had significantly greater declines in CD4 þ count than nonusers. Among subjects who initiated therapy, the same trend was observed, although failed to reach statistical significance despite having a larger estimated difference ( Table 2) . This difference could potentially reflect a treatment bias towards initiating treatment earlier in disease progression in nonusers. 39, 40 Limitations of this analysis include the relatively small number of injection drug users (n ¼ 76) and that the AIEDRP study only collected injection drug use as a risk factor for HIV and did not collect information on noninjection drug use, such as cocaine and morphine. We are therefore unable to quantify injection drug use exposure or identify whether a subset of subjects also had utilized stimulants and/or opiates. Thus, it is possible that a subgroup of injection drug using subjects had increased exposure or used additional drugs that would also exhibit an effect on disease progression. In addition, only subjects that had a viral load measurement were included in this analysis as viral load is an important predictor of CD4 þ decline; 38 however, a sensitivity analysis without adjusting for baseline viral load including all subjects found similar declines and differences between injection drug users and others.
Comparison to other models
Using a model that does not account for dropout time or reason, changes in CD4 þ count are reduced and the effect of injection drug use is attenuated and no longer statistically significant; drug use is associated with only a 0.065 log(cells/mm 3 ) steeper decline in log e (CD4 þ ) per year (95% CI: À0.135, 0.005; p ¼ 0.07). Using the model that accounts for dropout time and reason, the magnitude of the drug use association is 45% larger (Figures 5 and 6 ) than the unadjusted model. Additionally, in the extended model estimated changes in log e (CD4 þ ) for nonusers and drug users are 59.8% and 56.0% greater, respectively. Using the standard mixed model, injection drug users are estimated to have declines of only 21.3% per year (95% CI: 15.4-26.8%) and nonusers were estimated to have 16.0% per year (95% CI: 14.2%, 17.8%). These results suggest that models that do not account for dropout may be overly optimistic and underestimate changes in CD4 þ count over time for both injection drug users and nonusers. Using the standard mixed model that does not account for dropout, the average subject would be estimated to have a CD4 þ count of < 200 cells/mm 3 , the clinical definition of AIDS, at 4.2 years and 5.8 years for drug users and nonusers respectively; while using the model that accounts for dropout time and reason, this amount of decline would be expected in just 2.8 years and 3.7 years for injection drug users and nonusers, respectively.
Estimates from the model that accounts for only dropout time are slightly attenuated compared to the extended model that accounts for dropout reason as well. Differences in the change in log e (CD4 þ ) between drug users and nonusers are 13.7% larger using the extended model, and the estimated changes in log e (CD4 þ ) are 5.8% and 7.7% larger for nonusers and drug users, respectively. The extended model that accounts for dropout time and reason has increased flexibility compared to the model that only accounts for dropout time, since each dropout reason is allowed a separate natural cubic B-spline. In this example, the single natural cubic B-spline used in the model that accounted for dropout time only was flexible enough to fit the mean change in log e (CD4 þ ) at each dropout time, and produced fairly similar results to the extended model. However, the extended model may improve model fit, particularly if the forms of the dropout varying slopes are quite different across dropout reasons or are very complex.
Sensitivity analysis
These models assume that subjects continue on the same linear trajectory of log e (CD4 þ ) after dropout. If rather than continuing on the same CD4 þ trajectory after dropout, subjects had more rapid declines in CD4 þ , then CD4 þ declines and differences between injection drug users and others would be expected to be more extreme than predicted by this analysis. However, if declines in CD4 þ count attenuate after dropout, differences between injection drug users and nonusers may not remain statistically significant. The sensitivity of the results to this assumption was evaluated by determining the impact of a proportional attenuation, denoted (u), of log e (CD4 þ ) decline after dropout. 11, 32 For example, for (u) ¼ 0.5, a subject with an estimated decline of -0.4 log e (CD4 þ ) per year would be assigned a slope of -0.2 log e (CD4 þ ) per year after dropout. (u) ¼ 0 is equivalent to the estimated CD4 þ count at a subject's last observation carried forward, while (u) ¼ 1 results in the assumption that a subject continues on the same trajectory after dropout. (u) ¼ 0 serves as an unrealistic lower bound, as CD4 þ counts are known to decline over time in untreated subjects. For (u) ¼ 0.5, 0.25, 0, injection drug users have steeper declines in CD4 þ count than nonusers. For (u) ¼ 0.5, differences between injection drug users and nonusers at 2 and 3 years remain statistically significant and differences at 3 years remain significant with (u) ¼ 0.25 (Table 3) .
Discussion
Longitudinal studies are common in the literature with the potential for nonignorable dropout. In practice, we often encounter clinically distinct dropout reasons with the dropout time distribution depending on both the primary exposure variable and dropout reason. We propose a method to accommodate both dropout reason and dropout time that allows for estimation of both dropout reason specific and marginal effects for each exposure group. While accounting for dropout reason in addition to dropout time may not necessarily result in large changes to the marginal estimates compared to a model that accounts for only dropout time, adjusting for reason does allow for additional clinically important insights that may increase understanding of the dropout mechanism and what drives differences between exposure groups. For example, in our analysis of the effect of injection drug use on CD4 þ decline in untreated subjects in the AIEDRP, accounting for dropout time and reason revealed steeper declines and larger differences between injection drug users and others compared to a standard linear mixed model. By accounting for dropout reason in addition to time, we found that subjects that were removed from the analysis at treatment initiation demonstrated more rapid declines than those who were lost to follow-up, consistent with the concurrent treatment guidelines. Among subjects lost to follow-up, injection drug use was associated with significantly greater CD4 þ declines. Among subjects who initiated treatment, the same trend was observed, although failed to reach statistical significance despite having a larger estimated difference; this difference could potentially reflect a treatment bias towards initiating treatment in nonusers.
This approach can be implemented using standard software without imposing distributional assumptions on the dropout mechanism, and is broadly applicable to the analysis of longitudinal cohort data, where nonignorable dropout and different dropout reasons may obscure important relationships. In addition, this approach could also be utilized to treat administratively censored subjects and study completers separately from subjects that dropped out. 33, 41 Increasingly, longitudinal cohort data are being mined to investigate health-related questions and ultimately to develop public policy. Therefore, optimizing analysis of longitudinal cohort data is of the utmost importance. 
